Journal of Applied Physiology, Vol 63, Issue 2 479-484, Copyright © 1987 by American Physiological Society

ARTICLES

Effect of platelet-activating factor on airway vascular permeability: possible mechanisms

T. W. Evans, K. F. Chung, D. F. Rogers and P. J. Barnes
Department of Clinical Pharmacology, Brompton Hospital, London, United Kingdom.

We studied the effects of the potent inflammatory mediator, platelet-activating factor (PAF), on vascular permeability in airways (and other tissues) of guinea pigs by measuring extravasation of circulating Evans blue dye. PAF caused a dose-dependent increase in vascular permeability. At 1 ng/kg iv, PAF caused an increase in Evans blue extravasation of 220% (P less than 0.05) in the trachea, with the greatest effect at a dose of 100 ng/kg (858%; P less than 0.01). Histamine (150 micrograms/kg iv) caused a 320% increase over base line in the trachea and 200% in main bronchi; this effect was equivalent to that induced by 10 ng/kg PAF in the trachea and 1 ng/kg in main bronchi. The duration of effect of PAF was greatest in main bronchi (less than 10 min). Platelet depletion with a cytotoxic antibody, or the cyclooxygenase inhibitor, indomethacin, or the cyclooxygenase-lipoxygenase inhibitor, BW 7556, did not affect the vascular permeability response to PAF. The PAF-receptor antagonist, BN 52063, inhibited Evans blue extravasation in the airways in a dose-dependent manner, with complete inhibition at 5 mg/kg. Thus PAF-induced airway vascular leakage is mediated by specific receptors but not by products of arachidonic acid metabolism or by platelets. Increased airway microvascular leakage induced by PAF may lead to plasma extravasation and airway edema, factors that may contribute to the airway narrowing and hyperresponsiveness induced by PAF.

This article has been cited by other articles:

				S. Bayat, L. Porra, H. Suhonen, C. Nemoz, P. Suortti, and A. R. A. Sovijarvi Differences in the time course of proximal and distal airway response to inhaled histamine studied by synchrotron radiation CT J Appl Physiol, June 1, 2006; 100(6): 1964 - 1973. [Abstract] [Full Text] [PDF]

				S. Ishii, T. Nagase, H. Shindou, H. Takizawa, Y. Ouchi, and T. Shimizu Platelet-Activating Factor Receptor Develops Airway Hyperresponsiveness Independently of Airway Inflammation in a Murine Asthma Model J. Immunol., June 1, 2004; 172(11): 7095 - 7102. [Abstract] [Full Text] [PDF]

				M. E. Lekka, S. Liokatis, C. Nathanail, V. Galani, and G. Nakos The Impact of Intravenous Fat Emulsion Administration in Acute Lung Injury Am. J. Respir. Crit. Care Med., March 1, 2004; 169(5): 638 - 644. [Abstract] [Full Text] [PDF]

				R. Goggel, S. Hoffman, R. Nusing, S. Narumiya, and S. Uhlig Platelet-Activating Factor-induced Pulmonary Edema Is Partly Mediated by Prostaglandin E2, E-Prostanoid 3-Receptors, and Potassium Channels Am. J. Respir. Crit. Care Med., September 1, 2002; 166(5): 657 - 662. [Abstract] [Full Text] [PDF]

				E. I. Kitsiouli, G. Nakos, and M. E. Lekka Differential determination of phospholipase A2 and PAF-acetylhydrolase in biological fluids using fluorescent substrates J. Lipid Res., December 1, 1999; 40(12): 2346 - 2356. [Abstract] [Full Text] [PDF]

				G. NAKOS, E. I. KITSIOULI, and M. E. LEKKA Bronchoalveolar Lavage Alterations in Pulmonary Embolism Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1504 - 1510. [Abstract] [Full Text] [PDF]

				S. Mehta, J. Boudreau, C. M. Lilly, and J. M. Drazen Endogenous pulmonary nitric oxide in the regulation of airway microvascular leak Am J Physiol Lung Cell Mol Physiol, November 1, 1998; 275(5): L961 - L968. [Abstract] [Full Text] [PDF]

				K. Hattori, H. Adachi, A. Matsuzawa, K. Yamamoto, M. Tsujimoto, J. Aoki, M. Hattori, H. Arai, and K. Inoue cDNA Cloning and Expression of Intracellular Platelet-activating Factor (PAF) Acetylhydrolase II. ITS HOMOLOGY WITH PLASMA PAF ACETYLHYDROLASE J. Biol. Chem., December 20, 1996; 271(51): 33032 - 33038. [Abstract] [Full Text] [PDF]